The liver is one of our body’s most essential organs, performing over 500 vital functions,including metabolism, detoxification, and protein synthesis. When viral hepatitis threatens this critical organ, the consequences can be severe, ranging from acute illness to chronic disease, cirrhosis, and even liver cancer. For dental professionals and patients alike, understanding the importance of hepatitis prevention through vaccination is crucial for maintaining both systemic and oral health.
Viral hepatitis represents a significant global health challenge, with approximately 304 million people worldwide living with chronic hepatitis B or C infections as of 2022. What makes this particularly concerning is that only 13% of people with hepatitis B and 36% of people with hepatitis C have been diagnosed, meaning the vast majority are unaware of their condition, silently carrying and potentially transmitting these viruses. In the United States alone, there were approximately 86,000 estimated new hepatitis infections in 2023.
The impact extends far beyond liver health. Chronic viral hepatitis is responsible for 78% of primary liver cancers and 57% of liver cirrhosis cases globally, contributing to approximately one million deaths each year. For dental professionals, this underscores the critical importance of understanding hepatitis transmission and prevention in clinical settings.
Like what you’re learning? Download a brochure for our Orofacial Pain and Oral Medicine certificate or master’s degree program.
Hepatitis A: Prevention Through Vaccination
Hepatitis A virus (HAV) spreads through the fecal-oral route, making it particularly relevant in healthcare settings where proper hygiene protocols are essential. While historically children aged 2-18 had the highest infection rates (15 to 20 cases per 100,000), vaccination programs have dramatically reduced HAV incidence by 95.5% since their introduction in 1996.
The hepatitis A vaccine represents a remarkable success story in preventive medicine. Cell culture-adapted virus is grown in human fibroblasts, purified, inactivated with formalin, and combined with an aluminum hydroxide adjuvant. Single-antigen vaccines like Havrix (licensed 1995) and Vaqta (licensed 1996) provide excellent protection, while combination vaccines like Twinrix offer protection against both hepatitis A and B.
HAV vaccination is particularly important because the virus remains stable at low pH and requires high temperatures (185°F or higher) for inactivation. The vaccine provides long-lasting immunity and has virtually eliminated the large-scale outbreaks that once plagued communities. From 2016-2021, over 37,000 outbreak-associated cases were reported from 35 states, highlighting the continued importance of vaccination programs.
Hepatitis B: A Critical Vaccination Priority
Hepatitis B presents an even more serious threat, with the potential for chronic infection and long-term complications. The statistics are sobering: 350-400 million people worldwide have chronic hepatitis B, with the highest prevalence among Asian Pacific Islanders, Alaskan Eskimos, and populations in sub-Saharan Africa and central Asia.
The progression to chronic infection varies dramatically by age of exposure. While only 5% of adults develop chronic HBV infection, this percentage increases to 30-50% in children aged 1-5 years and reaches 90% in infants. This age-related susceptibility makes early vaccination absolutely critical.
Recombinant hepatitis B vaccines. Recombivax HB (1986), Engerix-B (1989), and the newer Heplisav-B (2017) have revolutionized prevention. These vaccines cannot cause HBV infection since they contain no potentially infectious viral DNA or complete viral particles. The vaccination provides nearly 100% protection when administered according to recommended schedules, typically beginning soon after birth with boosters a few weeks later.
In the United States, around 60,000 new cases of HBV infection occur annually, causing 5,000 deaths each year. However, vaccination programs have shown remarkable success data from 2000 to 2012 demonstrate a significant decline in reported cases from over 8,000 to approximately 3,000 annually.
Hepatitis C: The Challenge Without a Vaccine
Unlike hepatitis A and B, no vaccine exists for hepatitis C, making prevention through other means essential. HCV affects approximately 170 million people globally and has a concerning tendency toward chronicity, more than half of those infected develop chronic disease.
The absence of an HCV vaccine highlights the critical importance of infection control practices in dental settings. Healthcare providers must rely on universal precautions, proper sterilization protocols, and screening procedures to prevent the transmission of infections. The majority of patients at the beginning don’t have symptoms, don’t look or feel sick, and therefore don’t know they are infected¹⁰.
Dental Practice Implications
For dental professionals, hepatitis vaccination represents both a personal health imperative and a patient safety measure. The oral cavity can manifest signs of liver disease, including mucosal jaundice, bleeding disorders, petechiae, and increased bruising susceptibility. Patients with hepatitis may also experience distinctive breath odor, cheilitis, smooth atrophic tongue, dry mouth, and bruxism.
Recent research indicates that hepatitis C infection may increase the likelihood of Sjögren syndrome, sialadenitis, and oral lichen planus, conditions that dental professionals encounter regularly. Understanding these connections helps inform both diagnosis and treatment planning.
The liver’s role in drug metabolism is particularly relevant for dental practice². Many medications commonly used in dentistry are metabolized primarily by the liver, including local anesthetics (lidocaine, mepivacaine, prilocaine, bupivacaine), analgesics (aspirin, acetaminophen, codeine, meperidine, ibuprofen), antibiotics (ampicillin, tetracycline, metronidazole, vancomycin), and sedatives (diazepam, barbiturates). For patients with compromised liver function, medication selection and dosing require careful consideration.
Liver Function and Clinical Monitoring
Understanding liver function tests is crucial for dental professionals managing patients with potential hepatitis. Standard liver function biomarkers include alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, bilirubin, albumin, and prothrombin time⁴. Elevated AST/ALT ratios can help differentiate between various liver conditions, with drug-induced liver injury and chronic viral hepatitis showing predominantly ALT elevation (AST/ALT <1), while alcoholic hepatitis and cirrhosis typically show AST predominance (AST/ALT ≥1).
The liver’s remarkable regenerative capacity, the greatest of any organ in the body, involves complex interactions between various cellular components and immune cells. However, when injury exceeds regenerative capacity, liver transplantation becomes the treatment of choice, emphasizing the importance of prevention through vaccination.
Prevention Strategy and Public Health Impact
Vaccination programs have demonstrated remarkable success in reducing hepatitis incidence. The hepatitis B vaccination program represents one of modern medicine’s greatest achievements. By preventing chronic infection, these vaccines effectively prevent the progression to cirrhosis and hepatocellular carcinoma decades later. For healthcare workers, including dental professionals, vaccination is not just recommended, it’s essential for personal protection and patient safety.
Liver cancer is now the 4th leading cause of death from cancer worldwide and the 3rd in men. Given that chronic viral hepatitis accounts for the majority of these cases, prevention through vaccination takes on even greater significance.
Treatment Considerations
While prevention remains paramount, understanding current treatment options is important for comprehensive patient care. For chronic hepatitis B, antiviral therapies including tenofovir, entecavir, lamivudine, telbivudine, and adefovir are available, with treatment decisions based on HBV DNA levels, ALT elevation, and presence of cirrhosis. For pregnant women with high viral loads (>2 x 10⁵ international units/mL), antiviral therapy should be initiated in the late second or early third trimester to prevent transmission to the child.
Hepatitis C treatment has been revolutionized by direct-acting antivirals (DAAs). Simplified treatment algorithms now exist for treatment-naive adults without cirrhosis, with regimens like glecaprevir/pibrentasvir or sofosbuvir/velpatasvir providing high cure rates.
Conclusion
Hepatitis vaccines represent powerful tools in our fight against liver disease and its oral health manifestations. While we await the development of hepatitis C vaccines, the available vaccines for hepatitis A and B provide excellent protection when properly administered. For dental professionals and their patients, vaccination represents a cornerstone of preventive healthcare that protects not only individual health but community wellbeing.
As we continue to understand the intricate connections between liver health and oral health, the importance of hepatitis prevention becomes increasingly clear. Through vaccination, proper infection control, and continued education, we can significantly reduce the burden of viral hepatitis and its wide-ranging health consequences.
Earn an Online Postgraduate Degree in Orofacial Pain and Oral Medicine
Are you interested in a variety of issues focused on orofacial pain, medicine and sleep disorders? Consider enrolling in the Herman Ostrow School of Dentistry of USC’s online, competency-based certificate or master’s program in Orofacial Pain and Oral Medicine.
References
• Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017 Nov 6;27(21):R1147-R1151. doi: 10.1016/j.cub.2017.09.019. PMID: 29112863; PMCID: PMC5897118.
• Marin JJG, Serrano MA, Monte MJ, Sanchez-Martin A, Temprano AG, Briz O, Romero MR. Role of Genetic Variations in the Hepatic Handling of Drugs. Int J Mol Sci. 2020 Apr 20;21(8):2884. doi: 10.3390/ijms21082884. PMID: 32326111; PMCID: PMC7215464.
• Chiang J. Liver Physiology: Metabolism and Detoxification, Pathobiology of Human Disease, Academic Press, 2014, Pages 1770-1782, ISBN 9780123864574.
• Preziosi ME, Monga SP. Update on the Mechanisms of Liver Regeneration. Semin Liver Dis. 2017;37(2):141-151. doi:10.1055/s-0037-1601351.
• Michalopoulos GK, Bhushan B. Liver regeneration: biological and pathological mechanisms and implications. Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):40-55. doi: 10.1038/s41575-020-0342-4. Epub 2020 Aug 6. PMID: 32764740.
• Centers for Disease Control and Prevention. Hepatitis A VIS. Updated 2020.
• Centers for Disease Control and Prevention. Hepatitis B VIS. Updated 2021.
• World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016-2021. Geneva: WHO Press; 2016.
• American Dental Association. Oral Health Topics: Hepatitis.
• Vistoso Monreal A. Infectious Diseases Manual OFPM #727. Herman Ostrow School of Dentistry of USC, Fall Trimester 2023.
• World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024. License: CC BY-NC-SA 3.0 IGO.
• Centers for Disease Control and Prevention. 2023 Viral Hepatitis Surveillance Report. Atlanta, GA: US Department of Health and Human Services, CDC; 2024.
